Neurogastrx rakes in $45 mln Series A
Neurogastrx, Inc, a private biopharmaceutical company focused on developing therapies for gastrointestinal disorders affecting the enteric nervous system, has secured $45 million in Series A financing. The lead investors were 5AM Ventures, OrbiMed Advisors and venBio Partners. In conjunction with the financing, Jim O'Mara has been appointed CEO while Klaus Veitinger, a venture partner at OrbiMed Advisors, will become chairman of the board. Also, David Allison of 5AM Ventures, Aaron Royston of venBio and Kevin Koch will be joining the board of directors.
4 January 2018•1 min read
